Nicholas Investment Partners, LP Esperion Therapeutics, Inc. Transaction History

Nicholas Investment Partners, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 11, 2021	SELL	$24.2 - $35.76 $5.71 Million - $8.43 Million	-235,855 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$31.18 - $52.71 $6.31 Million - $10.7 Million	202,240 Added 601.64%	235,855 $8.77 Million
Q2 2020 Aug 12, 2020	SELL	$30.04 - $51.31 $1.58 Million - $2.69 Million	-52,503 Reduced 60.97%	33,615 $1.73 Million
Q1 2020 May 13, 2020	BUY	$27.44 - $73.84 $481,517 - $1.3 Million	17,548 Added 25.59%	86,118 $2.72 Million
Q4 2019 Feb 13, 2020	BUY	$35.4 - $59.82 $2.43 Million - $4.1 Million	68,570 New	68,570 $4.09 Million
Q1 2019 May 15, 2019	SELL	$40.11 - $53.57 $335,038 - $447,470	-8,353 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$36.99 - $59.11 $2.43 Million - $3.88 Million	-65,718 Reduced 88.72%	8,353 $384,000
Q3 2018 Nov 14, 2018	SELL	$40.74 - $51.41 $38,662 - $48,788	-949 Reduced 1.26%	74,071 $3.29 Million
Q2 2018 Aug 14, 2018	BUY	$36.2 - $76.4 $227,046 - $479,180	6,272 Added 9.12%	75,020 $2.94 Million
Q1 2018 May 15, 2018	BUY	$65.94 - $80.76 $4.53 Million - $5.55 Million	68,748 New	68,748 $4.97 Million

207

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $168M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Nicholas Investment Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Nicholas Investment Partners, LP with notifications on news.